Teva sues Corcept over mifepristone 'monopoly' for rare disorder

Teva Pharmaceuticals (TEVA.TA) sued rival drugmaker Corcept Therapeutics (CORT.O) in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome.